Physician profile
Lin Vanover
NPI 1518793793
$1,331.54
in general payments reported to CMS, 2019-2025
15 companies · $1,332 in 2025
The $1,332 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $463.71 | 2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $239.77 | 2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $151.73 | 2025 | Zepbound, Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $107.70 | 2025 | |
| Dexcom, INC. | $73.14 | 2025 | Dexcom G6 Transmitter |
| Medtronic, INC. | $56.63 | 2025 | Symplicity G3, Inceptiv |
| Pfizer INC. | $49.44 | 2025 | |
| Inspire Medical Systems, INC. | $40.70 | 2025 | Inspire |
| Phathom Pharmaceuticals, INC. | $33.89 | 2025 | Voquezna |
| Seqirus USA INC | $22.11 | 2025 | Flucelvax, Fluad |
| Abbvie INC. | $20.99 | 2025 | |
| Glaxosmithkline, LLC. | $20.68 | 2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $18.41 | 2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.75 | 2025 | Jardiance |
| Merck Sharp & Dohme LLC | $14.89 | 2025 | M-M-R II, Gardasil 9, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Vanover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.